29 April 2025 in Cardiology and Therapy
MTMeiramgul K. Tundybayeva
+1
Introduction May Measurement Month (MMM) is a global campaign with the aim to improve awareness of arterial hypertension (AH). Kazakhstan participated in the campaign in 2021, 2022 and 2023. Methods During the cross-sectional 2021–2023 MMM surveys, volunteer adults (≥ 18 years) from cities in Kazakhstan had their blood pressure (BP) measured three times in a seated position, and received a questionnaire on their demographics, lifestyle and medical history. In those not receiving antihypertensive treatment, AH was defined as a mean systolic and/or diastolic BP ≥ 140/90 mmHg. Results A total of 8231 individuals took part in the survey, with 1805 participants in 2021, 2410 participants in 2022 and 4016 participants in 2023. The prevalence of AH was estimated to be 37% in 2021 and 45% in 2022 and 2023. Of those identified as having AH, 51–70% were aware that they had the condition. Among those who were aware that they had AH, 68–91% were receiving antihypertensive therapy. However, 70–82% of treated participants were only receiving one to two drugs. BP was controlled to < 140/90 mmHg in 43–50% of treated participants and to < 130/80 mmHg in 15–16%. Conclusion The 2021, 2022 and 2023 MMM campaigns showed that high proportion of AH, a low level of AH awareness and inadequate BP control in Kazakhstan. Programs are needed to increase awareness of the risks of high BP and to improve the diagnosis and effective treatment of AH.
1 January 2026 in Actual Problems of Theoretical and Clinical Medicine
Relevance: Chronic heart failure remains a major public health challenge worldwide, characterized by increasing incidence and significant morbidity and mortality. Understanding epidemiological trends and changes associated with the COVID-19 and post-COVID-19 period is essential for optimizing healthcare strategies. Aim: To analyze the dynamics of CHF incidence and mortality in Almaty city and Almaty oblast during the pre-COVID-19 and COVID-19/post-COVID-19 periods, and to assess future trends up to 2030. Methods: A retrospective descriptive and analytical study was conducted using official statistical data from 2012 to 2025. Indicators of CHF incidence and mortality were analyzed in the general population and by sex. The study period was divided into pre-COVID-19 period (2012-2019) and COVID-19/post-COVID-19 period (2020-2025) phases. Absolute and relative changes were calculated, and time series analysis was performed. Forecasting was carried out using linear regression and ARIMA (0,0,0) models. Results: Chronic heart failure incidence increased in both regions. In Almaty city, the chronic heart failure incidence rate increased from 1,217.3 to 1,552.2 per 100,000 population (+27.5 %), while in Almaty oblast it increased from 145.7 to 755.1 per 100,000 population (+418.4 %). The most pronounced growth was observed after 2019. Incidence increased in both sexes, with a higher growth rate among men. Mortality declined in both regions over the study period. Comparison of the pre-COVID-19 and COVID-19/post-COVID-19 periods demonstrated higher incidence rates in both regions, whereas mean mortality rates decreased. Forecasting indicates a continued increase in incidence through 2030, with relatively stable or gradually decreasing mortality. Conclusion: The study demonstrates a growing burden of chronic heart failure, particularly in Almaty oblast, with increasing incidence and declining mortality. These findings highlight the need for strengthening early detection, preventive strategies, and long-term management of chronic heart failure, especially in regional healthcare settings.
20 February 2026 in Russian Journal of Cardiology
Aim. To assess the relationships between all-cause and cardiovascular mortality rates and demographics, medical statistics, and personnel characteristics of the population of the Republic of Kazakhstan. Material and methods. This retrospective analysis of official statistical data was conducted using quantitative methods and interregional comparisons. Nonparametric statistical methods were used. Results. The all-cause mortality rate increased from 6,98‰ in 2019 to 9,34‰ in 2021 (+33,8%), followed by a decrease in 2022-2024 to 6,42-6,59‰. In the pre-COVID-19 period, a steady decline in mortality was observed (an average annual change of -2,06%). No significant trend was observed in the post-COVID-19 period. We found a negative correlation between mortality and the incidence of cardiovascular diseases (τ=-0,689; p=0,005) and a positive correlation with the incidence of tumors and the availability of outpatient specialists (p<0,05). The regression model explained approximately 65% of the variance in mortality (R 2 ≈0,65). Conclusion. The obtained results highlight the key role of primary health care in reducing cardiovascular mortality and the need for further development of preventive programs aimed at early detection and control of risk factors.